Author: OneMedPlace Team
Delmar Pharmaceuticals (DMPI) is a clinical and early stage Oncologyl Company focused on developing and commercializing leading anti-cancer therapies in high impact orphan oncological indications specifically where patients have failed contemporary therapy. Delmars’ lead drug candidate ‘VAL-083’ is a first in-class anti-cancer (specifically lung, brain, cervical, ovarian tumors and Leukemia) pharmacological alkylating agent. VAL-083 has been approved in China as a cancer chemotherapeutic for treatment of Chornic Myolegenous Leukemia (CML) and lung cancer. DMPI commenced their Phase I/II study of VAL-083 in patients with recurrent malignant glioma or progressive secondary brain tumor in 2011.
Commercial experience in China has demonstrated fewer side effects when compared to other alkylating agents. Recently, DMPI was awarded a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a U.S. patent application specifying protocols and methods for synthesizing their lead drug candidate, VAL-083.
DMPI presented this powerful data at the 2013 OneMedForum NY as well as their numerous possible routes they can potentially take the company from this point forward. Some of which include: expansion of clinical sites, form a marketing partnership with China, and expanding clinical development. Be sure to stay updated on their world-wide expansion. Market Cap: $24.7 million; Volume: 6,200; 12 Month Trail: $1.00-$3.40.
View the company site here: (http://www.delmarpharma.com/)
View the profile page here: (http://www.onemedplace.com/database/list/cid/14438/)